Keywords

chronic kidney disease, diabetes, dialysis, dulaglutide, end-stage renal disease, exenatide, glucagon-like peptide-1 receptor agonist, liraglutide, lixisenatide, semaglutide, type 2 diabetes mellitus

Authors

1. Aldrich, Sarah PharmD
2. Ashjian, Emily PharmD, BCPS, BCACP

Abstract

Abstract: Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.